Statin Rx-To-Oh-We’ll See: Bristol’s Dolan Guarded On Pravachol Switch

Broad regulatory concerns over drug safety across classes reduce the chances of an Rx-to-OTC statin switch, according to Bristol-Myers Squibb CEO Peter Dolan